File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Rapamycin prevents the development of nephritis in lupus-prone NZB/W F 1 mice

TitleRapamycin prevents the development of nephritis in lupus-prone NZB/W F 1 mice
Authors
KeywordsAutoimmunity
Lupus nephritis
NZB/W F1 mice
Rapamycin
Issue Date2008
PublisherSage Publications Ltd. The Journal's web site is located at http://lup.sagepub.com
Citation
Lupus, 2008, v. 17 n. 4, p. 305-313 How to Cite?
AbstractRapamycin is a potent immunosuppressive drug currently used mainly for rejection prophylaxis in renal transplantation. The aim of this study was to determine the effect of rapamycin treatment on the development of nephritis in lupus-prone New Zealand Black/White F1 (NZB/W F1) mice. Twelve-week-old female NZB/W F1 mice were treated with rapamycin (3 mg/kg body weight) or saline once daily by oral gavage for 20 weeks. The severity of nephritis was assessed by clinical and biochemical parameters, renal histology, immunohistochemistry and gene expression studies. Rapamycin treatment markedly reduced proteinuria, improved renal function, decreased serum anti-double stranded DNA antibody levels and diminished splenomegaly. Kidney sections from saline-treated mice showed marked mesangial proliferation, tubular dilation with protein cast deposition and interstitial inflammatory cell infiltration. Rapamycin-treated mice had near normal renal histology, with marked reduction in glomerular immune deposition and the infiltration by T cells, B cells and macrophages. Rapamycin treatment was associated with down-regulation of intra-renal expression of monocyte chemoattractant protein-1 (MCP-1) mRNA and protein. We conclude that rapamycin is highly effective in preventing the development of nephritis in NZB/W F1 mice. The beneficial effects of rapamycin are mediated through inhibition of lymphoproliferation and reduced MCP-1 expression. © 2008 SAGE Publications.
Persistent Identifierhttp://hdl.handle.net/10722/148559
ISSN
2015 Impact Factor: 2.118
2015 SCImago Journal Rankings: 0.878
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLui, SLen_HK
dc.contributor.authorYung, Sen_HK
dc.contributor.authorTsang, Ren_HK
dc.contributor.authorZhang, Fen_HK
dc.contributor.authorChan, KWen_HK
dc.contributor.authorTam, Sen_HK
dc.contributor.authorChan, TMen_HK
dc.date.accessioned2012-05-29T06:13:43Z-
dc.date.available2012-05-29T06:13:43Z-
dc.date.issued2008en_HK
dc.identifier.citationLupus, 2008, v. 17 n. 4, p. 305-313en_HK
dc.identifier.issn0961-2033en_HK
dc.identifier.urihttp://hdl.handle.net/10722/148559-
dc.description.abstractRapamycin is a potent immunosuppressive drug currently used mainly for rejection prophylaxis in renal transplantation. The aim of this study was to determine the effect of rapamycin treatment on the development of nephritis in lupus-prone New Zealand Black/White F1 (NZB/W F1) mice. Twelve-week-old female NZB/W F1 mice were treated with rapamycin (3 mg/kg body weight) or saline once daily by oral gavage for 20 weeks. The severity of nephritis was assessed by clinical and biochemical parameters, renal histology, immunohistochemistry and gene expression studies. Rapamycin treatment markedly reduced proteinuria, improved renal function, decreased serum anti-double stranded DNA antibody levels and diminished splenomegaly. Kidney sections from saline-treated mice showed marked mesangial proliferation, tubular dilation with protein cast deposition and interstitial inflammatory cell infiltration. Rapamycin-treated mice had near normal renal histology, with marked reduction in glomerular immune deposition and the infiltration by T cells, B cells and macrophages. Rapamycin treatment was associated with down-regulation of intra-renal expression of monocyte chemoattractant protein-1 (MCP-1) mRNA and protein. We conclude that rapamycin is highly effective in preventing the development of nephritis in NZB/W F1 mice. The beneficial effects of rapamycin are mediated through inhibition of lymphoproliferation and reduced MCP-1 expression. © 2008 SAGE Publications.en_HK
dc.languageengen_US
dc.publisherSage Publications Ltd. The Journal's web site is located at http://lup.sagepub.comen_HK
dc.relation.ispartofLupusen_HK
dc.subjectAutoimmunityen_HK
dc.subjectLupus nephritisen_HK
dc.subjectNZB/W F1 miceen_HK
dc.subjectRapamycinen_HK
dc.subject.meshAdministration, Oralen_US
dc.subject.meshAnimalsen_US
dc.subject.meshAntibodies, Antinuclear - Immunologyen_US
dc.subject.meshCell Proliferation - Drug Effectsen_US
dc.subject.meshChemokine Ccl2 - Biosynthesis - Geneticsen_US
dc.subject.meshCytokinesen_US
dc.subject.meshDisease Models, Animalen_US
dc.subject.meshDose-Response Relationship, Drugen_US
dc.subject.meshFemaleen_US
dc.subject.meshGene Expressionen_US
dc.subject.meshImmunohistochemistryen_US
dc.subject.meshImmunosuppressive Agents - Administration & Dosageen_US
dc.subject.meshKidney Glomerulus - Immunology - Metabolism - Pathologyen_US
dc.subject.meshLupus Nephritis - Immunology - Pathology - Prevention & Controlen_US
dc.subject.meshMiceen_US
dc.subject.meshMice, Inbred Nzben_US
dc.subject.meshRna, Messenger - Geneticsen_US
dc.subject.meshReverse Transcriptase Polymerase Chain Reactionen_US
dc.subject.meshSirolimus - Administration & Dosageen_US
dc.subject.meshT-Lymphocytes - Immunologyen_US
dc.titleRapamycin prevents the development of nephritis in lupus-prone NZB/W F 1 miceen_HK
dc.typeArticleen_HK
dc.identifier.emailYung, S:ssyyung@hku.hken_HK
dc.identifier.emailChan, KW:hrmtckw@hku.hken_HK
dc.identifier.emailChan, TM:dtmchan@hku.hken_HK
dc.identifier.authorityYung, S=rp00455en_HK
dc.identifier.authorityChan, KW=rp00330en_HK
dc.identifier.authorityChan, TM=rp00394en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1177/0961203307088289en_HK
dc.identifier.pmid18413412-
dc.identifier.scopuseid_2-s2.0-43249109614en_HK
dc.identifier.hkuros142656-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-43249109614&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume17en_HK
dc.identifier.issue4en_HK
dc.identifier.spage305en_HK
dc.identifier.epage313en_HK
dc.identifier.eissn1477-0962-
dc.identifier.isiWOS:000255733500008-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridLui, SL=7102379130en_HK
dc.identifier.scopusauthoridYung, S=22636568800en_HK
dc.identifier.scopusauthoridTsang, R=7102940073en_HK
dc.identifier.scopusauthoridZhang, F=35735768800en_HK
dc.identifier.scopusauthoridChan, KW=16444133100en_HK
dc.identifier.scopusauthoridTam, S=7202037323en_HK
dc.identifier.scopusauthoridChan, TM=7402687700en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats